Novo Nordisk: GLP-1's Concerns Are Overblown

Novo Nordisk has experienced U.S. market share erosion from Eli Lilly and compounded semaglutide, leading to a downward revision of FY25 sales guidance. Despite these challenges, the company maintains a robust pipeline of next-generation GLP-1s, including advanced oral formulations and highly effective multi-agonists like Amycretin, positioning it for future growth in an underpenetrated obesity market. With a new CEO focusing on international expansion and cost efficiencies, coupled with an attractive valuation at FY25 EV/EBITDA of 10.2x, the article suggests investor concerns regarding its GLP-1 franchise may be overstated.

Analysis

Novo Nordisk (NVO) is navigating significant competitive headwinds, evidenced by a loss of U.S. market share to Eli Lilly (LLY) and a downward revision of its FY25 guidance for sales growth to 8-14% and operating income growth to 10-16%. This pressure is compounded by competition from compounded semaglutide, prompting over 100 lawsuits from Novo. Despite these challenges, the company's valuation appears compelling following a 60% share-price drawdown, trading at an FY25 EV/EBITDA of 10.2x and a P/E of 13.5x. The long-term outlook is supported by a robust pipeline aimed at competing with LLY, including an oral version of Semaglutide targeting a 2026 launch and the next-generation dual-agonist Amycretin, which showed 24.3% weight loss in early trials and could be a blockbuster competitor to LLY's Retatrutide post-2029. Strategically, a new CEO is implementing significant cost savings of $1.25 billion annually to be reinvested in commercial and R&D initiatives, with a heightened focus on international markets where Novo still holds a 71% share. The company's financial health remains strong with ROE consistently above 60% and free cash flow expected to nearly double in 2026 as heavy manufacturing investments subside.

Key Decisions for Investors

• Consider the current valuation as a potentially attractive entry point for a long-term position, as the 60% share-price decline and low forward multiples (10.2x FY25 EV/EBITDA) suggest near-term competitive pressures may be fully priced in.
• Closely monitor pipeline catalysts, particularly the FDA decision on oral Semaglutide in late 2025 and progress on Amycretin's Phase 3 trials, as these are critical for Novo's ability to defend and regain market share in the latter half of the decade.
• Evaluate the new CEO's ability to execute on international growth and effectively redeploy the $1.25 billion in cost savings, as this strategic shift is fundamental to the bull case.
• Watch for stabilization in U.S. market share figures through 2025; a continued decline would be the primary risk factor, potentially signaling deeper competitive issues and margin pressure.